#ASH17: The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlight – Endpoints News
|
#ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlight
Endpoints News A few days ago, Celgene $CELG launched the pivotal Phase II/III study that will dictate the future of the BCMA-targeting bb2121, the CAR-T in-licensed from bluebird bio $BLUE. And if they come close to the data that bluebird has on offer at ASH this … |
